Edition:
India

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

77.53EUR
23 Nov 2017
Change (% chg)

€-0.04 (-0.05%)
Prev Close
€77.57
Open
€77.51
Day's High
€77.94
Day's Low
€76.99
Volume
259,007
Avg. Vol
441,525
52-wk High
€89.75
52-wk Low
€53.84

Select another date:

Fri, Oct 27 2017

BRIEF-Galapagos NV reports Q3 loss of ‍1.75​ euro per share

* Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​

BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106

* Co, Morphosys report first promising signs of clinical activity in phase 1 study with IL-17C antibody MOR106 in Atopic Dermatitis patients

BRIEF-Galapagos says GLPG1690 halts disease progression in IPF patients in mid-stage trial

* GLPG1690 halts disease progression in IPF patients in Flora phase 2A trial

BRIEF-Galapagos H1 revenues up at EUR 73.0 mln

* ANNOUNCED ON THURSDAY H1 REVENUES EUR 73.0 MLN VS EUR 48.8 MLN YEAR AGO

BRIEF-Servier announces it has exercised option to develop osteoarthritis molecule from Galapagos

* SERVIER ANNOUNCES IT HAS EXERCISED OPTION TO DEVELOP NOVEL OSTEOARTHRITIS MOLECULE GLPG1972/S201086 FROM GALAPAGOS NV, OBTAINING GLOBAL COMMERCIAL RIGHTS OUTSIDE THE U.S.

BRIEF-Galapagos announces new phase 2 study with filgotinib

* NEW PHASE 2 STUDY WITH FILGOTINIB IN NON-INFECTIOUS UVEITIS‍​

BRIEF-Galapagos announces successful completion of Phase 1

* GALAPAGOS' RESEARCH AND DEVELOPMENT UPDATE 2017: RAPIDLY ADVANCING OUR PRODUCT CANDIDATES

Select another date: